GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » Equity-to-Asset

Estrella Immunopharma (Estrella Immunopharma) Equity-to-Asset : 0.98 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Estrella Immunopharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $8.50 Mil. Estrella Immunopharma's Total Assets for the quarter that ended in Mar. 2024 was $8.63 Mil.

The historical rank and industry rank for Estrella Immunopharma's Equity-to-Asset or its related term are showing as below:

ESLA' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.12   Med: 0.37   Max: 0.98
Current: 0.98

During the past 1 years, the highest Equity to Asset Ratio of Estrella Immunopharma was 0.98. The lowest was -2.12. And the median was 0.37.

ESLA's Equity-to-Asset is ranked better than
99.16% of 1556 companies
in the Biotechnology industry
Industry Median: 0.67 vs ESLA: 0.98

Estrella Immunopharma Equity-to-Asset Historical Data

The historical data trend for Estrella Immunopharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Equity-to-Asset Chart

Estrella Immunopharma Annual Data
Trend Jun21
Equity-to-Asset
-

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.12 - 0.37 0.96 0.98

Competitive Comparison of Estrella Immunopharma's Equity-to-Asset

For the Biotechnology subindustry, Estrella Immunopharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Estrella Immunopharma's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Estrella Immunopharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Estrella Immunopharma's Equity-to-Asset falls into.



Estrella Immunopharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Estrella Immunopharma's Equity to Asset Ratio for the fiscal year that ended in Jun. 2021 is calculated as

Equity to Asset (A: Jun. 2021 )=Total Stockholders Equity/Total Assets
=0/0
=

Estrella Immunopharma's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=8.495/8.633
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Estrella Immunopharma  (NAS:ESLA) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Estrella Immunopharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Estrella Immunopharma (Estrella Immunopharma) Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines